Leucocyte interferon-α retreatment for chronic hepatitis C patients previously intolerant to other interferons

Journal of Viral Hepatitis

Volumn 5, Issue 5, 1998, Pages 333-339

  Cacopardo, B ^a,b   Benanti, F ^a   Brancati, G ^a   Romano, F ^a   Nunnari, A ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE   (Italy)

Author keywords

Chronic active hepatitis C; Efficacy; Leucocyte IFN ; Lymphoblastoid IFN ; Retreatment; Tolerability

Indexed keywords

ALPHA INTERFERON A; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEPATITIS C; HUMAN; LEUKOPENIA; MALE; MENTAL DISEASE; PRIORITY JOURNAL; RETREATMENT; THROMBOCYTOPENIA; THYROID DISEASE;

ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0031683057     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00113.x     Document Type: Article

References (25)

1. Tinè F, Magrin S, Craxì A, Pagliaro L. Interferon for nonA and nonB chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-199.
2. Cammà C, Giunta M, Almasio P, Di Marco V, Craxì A. Moving towards the optimal treatment of chronic hepatitis C. Ital J Gastroenterol Hepatol 1997; 29: 69-74.
3. Magrin S, Craxì A, Fabiano C et al. Serum hepatitis C virus RNA and response to alpha interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992; 38: 200-206.
4. Niederau C, Heintges T, Haussinger D. Treatment of chronic nonA nonB and C hepatitis with alfa-interferon: a meta-analysis of dose and duration. Hepatology 1995; 22: 153A(abstr).
5. Vaccaro A, Giunta M, Lo Iacono A, Craxì A. Retreatment with leukocyte interferon of chronic hepatitis C patients non responders to recombinant interferon. J Hepatol 1997; 26 (suppl 1): 197 (abstr).
6. Gattoni A, Romano C, Cecere A, Caiazzo R, Grima P, Altucci P. Efficacy of human leukocyte interferon treatment in elderly patients with hepatitis C virus-related chronic liver disease. Arch Gerontol Geriatr 1996; suppl 5: 305-312.
7. Poynard T, Leroy V, Mathurin P, Cohard M. Opalan P, Zarski JP. Treatment of chronic hepatitis C by interferon for longer duration than 6 months. Dig Dis Sci 1996; 41: 99S-102S.
8. Pawtowsky JM, Roudot-Thoraval F, Bastie A et al. Factors affecting treatment responses to interferon alfa in chronic hepatitis C. J Infect Dis 1996; 174: 1-7.
9. Magrin S, Craxì A, Fabiano C et al. HCV viremia is more important than genotype as a predictor of response to interferon in Sicily (southern Sicily). J Hepatol 1996; 25: 583-590.
10. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
11. Di Marco V, Lo Iacono O, Cammà C et al. A randomized controlled trial of high dose maintenance interferon therapy in chronic hepatitis C. J Med Virol 1997; 51: 17-24.
12. Lin R, Roach E, Zimmermann M, Strasser S, Parrel GC for the Australian Hepatitis C Study Group. Interferon alfa 2b for chronic hepatitis C: effect of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. J Hepatol 1995; 23: 487-496.
13. Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon alpha on alanine aminotransferase in patients with chronic hepatitis C or chronic nonA nonB hepatitis. A meta-analysis. Clin Drug Invest 1995; 9: 239-254.
14. Enriquez J, Torras X, Miralles F et al. Comparative study of 2 high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence of the levels of ALT, viraemia and histologic activity. J Viral Hep 1995; 2: 181-187.
15. Malaguarnera M, Restuccia S, Trovato G, Siciliano R, Motta M, Trovato B. Treatment with alpha interferons in patients with chronic hepatitis C. A meta-analysis. Clin Drug Invest 1995; 9: 141-149.
16. Renault PF, Hoofnagle JH. Side effects of alpha interferons. Semin Liver Dis 1989; 9: 273-277.
17. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115-150.
18. Fattovich G, Giustina G, Favarato S, Ruol A and Investigators of the Italian Association for the Study of the Liver. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47.
19. Okanoue T, Sakamoto S, Itah Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
20. Renault PF, Hoofnagle JH, Park Y et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987; 147: 1577-1580.
21. Cagnoni C, Pancotti D, Carrara GC. Correlazioni fra efficacia e tollerabilità nella terapia dell'epatite cronica attiva da HCV con alfa IFN. Proceedings of 'Convegno Nazionale Terapia dell'epatite cronica C: 10 anni di esperienze' (abstr). Taormina, 28 Feb-2 March 1997.
22. Shiratori Y, Yokosuka O, Imazaki F, Hashimoto E, Hayashi N. Viral eradication rate is proportional to the total dose of interferon: 'Tokyo-Chiba' hepatitis C multicentric, randomized and prospective study (abstr). Proceedings of the Digestive Diseases Week, San Francisco, CA, 19-22 May 1996.
23. Gordon SC. Natural alpha interferon treatment of chronic hepatitis C in patients refractory to recombinant interferon alfa2b. Hepatology 1995; 22: 117A (abstr).
24. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Tomasello FB, Rampello L. IFN alfa-induced depression in HCV patients (abstr). Proceedings of the 32nd Annual Meeting of the European Association for the Study of The Liver. London, 9-12 April 1997.
25. Fattovich G, Betterle C, Brollo L et al. Autoantibodies during α-interferon therapy for chronic hepatitis B. J Med Virol 1991; 34: 132-135.